Business Context and Reporting Period
Pavmed Inc., an emerging growth company incorporated in Delaware, filed this Form 8-K on January 23, 2018. The report details the closing of a previously announced firm commitment underwritten public offering of common stock.
Key Financial Metrics
- Shares Issued: 2,415,278 shares of common stock ($0.001 par value).
- Offering Price: $1.80 per share.
- Net Proceeds: Approximately $3.9 million (excluding the overallotment option) after underwriting discounts, commissions, and offering expenses.
- Underwriter: Dawson James Securities, Inc. (sole underwriter).
- Overallotment Option: The underwriter holds a 45-day option to purchase up to 362,292 additional shares.
The filing does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity metrics as this is a transactional report regarding a capital raise.
Material Changes
The primary material change is the increase in the company's cash position resulting from the net proceeds of the public offering. The filing does not provide comparative financial data against prior periods.
Guidance, Outlook, and Risks
Management commentary is limited to the announcement of the offering's consummation. The filing does not contain updated financial guidance, specific risk factors, or contingencies beyond the standard terms of the underwriting agreement and the potential exercise of the overallotment option.
Investor Verification Checklist
- Verify the final net proceeds received after all offering expenses are finalized.
- Monitor whether the underwriter exercises the 45-day overallotment option for up to 362,292 additional shares.
- Review the attached press release (Exhibit 99.1) for details on the intended use of proceeds.
- Confirm the updated share count and dilution impact on existing shareholders.